Forssman-like antibody levels in sera of patients with lung cancer. 1979

H Kitamura, and P Levine, and P J Cheng, and R A Egeli, and Y P Liu, and R A Good, and N K Day

Sera of normal individuals or patients with lung cancer were assayed for Forssman-like antibody by a quantitative and specific method using ethylenediaminetetraacetate-containing buffer to inactivate complement in the test serum. It was shown that although Forssman-like antibody levels were distributed widely, (a) the levels of young (20 to 45 years of age) normal subjects of Blood Groups A and AB were lower than those of Blood Groups O and B, (b) the levels of old (60 to 80 years of age) normal subjects were lower than those of young normal subjects of Blood Groups O and B, and (c) the levels of old lung cancer patients were lower when compared to age-matched normal individuals of their blood group.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D005577 Forssman Antigen A glycolipid, cross-species antigen that induces production of antisheep hemolysin. It is present on the tissue cells of many species but absent in humans. It is found in many infectious agents. Antigen, Forssman
D006358 Hot Temperature Presence of warmth or heat or a temperature notably higher than an accustomed norm. Heat,Hot Temperatures,Temperature, Hot,Temperatures, Hot
D006461 Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity. Haemolysis,Extravascular Hemolysis,Intravascular Hemolysis,Extravascular Hemolyses,Haemolyses,Hemolyses, Extravascular,Hemolyses, Intravascular,Hemolysis, Extravascular,Hemolysis, Intravascular,Intravascular Hemolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000017 ABO Blood-Group System The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane. ABH Blood Group,ABO Blood Group,ABO Factors,Blood Group H Type 1 Antigen,H Blood Group,H Blood Group System,ABO Blood Group System,Blood Group, ABH,Blood Group, ABO,Blood Group, H,Blood-Group System, ABO,Factors, ABO,System, ABO Blood-Group
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age

Related Publications

H Kitamura, and P Levine, and P J Cheng, and R A Egeli, and Y P Liu, and R A Good, and N K Day
February 1987, Nihon Gan Chiryo Gakkai shi,
H Kitamura, and P Levine, and P J Cheng, and R A Egeli, and Y P Liu, and R A Good, and N K Day
January 1982, Immunological communications,
H Kitamura, and P Levine, and P J Cheng, and R A Egeli, and Y P Liu, and R A Good, and N K Day
April 1989, Cancer,
H Kitamura, and P Levine, and P J Cheng, and R A Egeli, and Y P Liu, and R A Good, and N K Day
June 1981, The Japanese journal of experimental medicine,
H Kitamura, and P Levine, and P J Cheng, and R A Egeli, and Y P Liu, and R A Good, and N K Day
October 2006, Interactive cardiovascular and thoracic surgery,
H Kitamura, and P Levine, and P J Cheng, and R A Egeli, and Y P Liu, and R A Good, and N K Day
April 1981, The Japanese journal of experimental medicine,
H Kitamura, and P Levine, and P J Cheng, and R A Egeli, and Y P Liu, and R A Good, and N K Day
January 1998, Anticancer research,
H Kitamura, and P Levine, and P J Cheng, and R A Egeli, and Y P Liu, and R A Good, and N K Day
August 1983, Gan,
H Kitamura, and P Levine, and P J Cheng, and R A Egeli, and Y P Liu, and R A Good, and N K Day
January 1991, Oncology,
H Kitamura, and P Levine, and P J Cheng, and R A Egeli, and Y P Liu, and R A Good, and N K Day
January 1974, Surgical forum,
Copied contents to your clipboard!